From Stock head:“We think we have been substantially undervalued, and the market is finally recognising our value,” she said.
The company is focused on early cancer detection through simple, cost-effective blood tests that could save lives.
“Our multi-product pipeline covers some of the world’s most common and deadliest cancers in multi-billion dollar markets for ovarian, breast, prostate, and pancreatic cancers,” Dr Hinch wrote in an email.
Bard1 has a number of potential value inflection points coming up, including registering its hTERT cancer blood test in South Korea this quarter, and launching its exosome purification platform next quarter.
“We’ve got a lot going on as a business, it’s going be an exciting year for Bard1 and shareholders,” Dr Hinch said.
- Forums
- ASX - By Stock
- BD1 Pipeline
From Stock head:“We think we have been substantially...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IIQ (ASX) to my watchlist
(20min delay)
|
|||||
Last
48.5¢ |
Change
-0.015(3.00%) |
Mkt cap ! $44.62M |
Open | High | Low | Value | Volume |
50.0¢ | 50.0¢ | 48.5¢ | $3.031K | 6.133K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | 48.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
50.0¢ | 6396 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | 0.485 |
1 | 2060 | 0.480 |
1 | 2082 | 0.475 |
2 | 18750 | 0.470 |
2 | 18332 | 0.450 |
Price($) | Vol. | No. |
---|---|---|
0.500 | 6396 | 1 |
0.505 | 6024 | 1 |
0.520 | 7232 | 1 |
0.540 | 10000 | 1 |
0.545 | 11000 | 1 |
Last trade - 15.27pm 07/05/2024 (20 minute delay) ? |
Featured News
IIQ (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
Previous Video
Next Video
SPONSORED BY The Market Online